300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Social Impact
Oil and Gas
Retail
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Theatre
Music
Art
Medical
Real Estate
Recruiting
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Web3
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Oceania
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Andorra
Colombia
Sudan
China
Armenia
Costa Rica
Kuwait
Czech Republic
Kenya
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Paraguay
Botswana
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United Kingdom
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Argentina
Qatar
Belgium
Barbados
Jordan
Austria
Bangladesh
Ethiopia
Azerbaijan
Bulgaria
Bahamas
Ecuador
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Faroe Islands
Estonia
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Jersey
Lithuania
Bahrain
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
CRISPR Therapeutics, VC Fund

CRISPR Therapeutics

VC Fund

Cambridge, United States

CRISPR Therapeutics is a VC fund in Cambridge focused on Biotechnology. CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from theirscientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Total investments:
1
Last investment:
Lead investor:
0%

Last updated:

Industries CRISPR Therapeutics invests in

Biotechnology

Stages CRISPR Therapeutics invests in

Series A

Countries CRISPR Therapeutics invests in

United States

Contacts

NameEmailPhoneSocials
Julianne Bruno Julianne Bruno
Andrew Kernytsky
Chris Gemmiti Chris Gemmiti
Craig Mello Craig Mello
Daniel Anderson Daniel Anderson

Sign up to unlock verified contacts

Unlock Contacts

Team

NameTitleInvestmentsLinksEmail
Julianne Bruno
Julianne Bruno Chief Operating Officer
Chief Operating Officer Total investments: 1
Find email
Andrew Kernytsky Senior Director, Head of Genomics and Computational Biology
Senior Director, Head of Genomics and Computational Biology Total investments: 0 Find email
Chris Gemmiti
Chris Gemmiti Executive Director of Technical Operations
Executive Director of Technical Operations Total investments: 0 Find email
Craig Mello
Craig Mello Scientific Founders
Scientific Founders Total investments: 0 Find email
Daniel Anderson
Daniel Anderson Scientific Founders
Scientific Founders Total investments: 0 Find email
See all 8 team members →

Investments

CompanyDescriptionRoundLinks
Averna Therapeutics Averna Therapeutics
Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells. $85M / Series A / Jun 25, 2024

Co-Investors

Arc Ventures Arc Ventures 1 deal together
Deep-Insight Deep-Insight 1 deal together
Deep Insight Deep Insight 1 deal together
Delos Capital Delos Capital 1 deal together
Innovation Endeavors Innovation Endeavors 1 deal together Insight Partners Insight Partners 1 deal together

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Social Impact
Oil and Gas
Retail
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Theatre
Music
Art
Medical
Real Estate
Recruiting
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Web3
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Oceania
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Andorra
Colombia
Sudan
China
Armenia
Costa Rica
Kuwait
Czech Republic
Kenya
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Paraguay
Botswana
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United Kingdom
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Argentina
Qatar
Belgium
Barbados
Jordan
Austria
Bangladesh
Ethiopia
Azerbaijan
Bulgaria
Bahamas
Ecuador
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Faroe Islands
Estonia
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Jersey
Lithuania
Bahrain
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does CRISPR Therapeutics invest in?

CRISPR Therapeutics invests primarily in Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact CRISPR Therapeutics?

Public channels for CRISPR Therapeutics include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at CRISPR Therapeutics?

The team at CRISPR Therapeutics includes Julianne Bruno (Chief Operating Officer), Andrew Kernytsky (Senior Director, Head of Genomics and Computational Biology) and Chris Gemmiti (Executive Director of Technical Operations), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
CRISPR Therapeutics CRISPR Therapeutics Find emails